NCT02725866View on ClinicalTrials.gov

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C

CompletedOBSERVATIONAL
Enrollment

216

Participants

Timeline

Start Date

April 5, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Chronic Hepatitis C
Interventions
DRUG

Paritaprevir/ritonavir/ombitasvir

Co-formulated tablet

DRUG

Dasabuvir

Tablet

DRUG

Ribavirin

Tablet

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY